Wolfgang Miesbach: How ‘Benign’ PDE Inhibitors Shape Platelet Function
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn about a recent article by Meinrad Paul Gawaz et al, published in ScienceDirect:
”Do ‘benign’ PDE inhibitors quietly shape platelet function?
A recent study by Meinrad Paul Gawaz and co-authors from the University of Tübingen investigates how different phosphodiesterase (PDE) inhibitors modulate platelet signalling and thrombus formation via cAMP/cGMP pathways.
What the authors explored
They compared:
- A broad PDE blocker
- A PDE‑3–preferring inhibito
- A PDE‑5 inhibitor
…across platelet activation, aggregation assays and a collagen flow‑chamber models:
- ADP/P2Y12‑ and TRAP/PAR1‑driven platelet responses are more sensitive to PDE inhibition than collagen/GPVI signalling.
- Robust inhibition of activation and aggregation requires broad or combined PDE targeting, rather than blocking a single isoform.
- Under arterial shear, all tested inhibitors – including a PDE‑5 blocker – reduce thrombus formation, revealing effects not seen in routine PRP assays.
Why this matters
For patients on chronic PDE‑3/5 therapy (e.g. for vascular disease, pulmonary hypertension, erectile dysfunction), there may be a ‘hidden’ antithrombotic modulation that becomes clinically relevant when combined with aspirin, P2Y12 inhibitors or DOACs.”
Title: Effect of phosphodiesterase inhibitors on platelet function
Authors: Ravi Hochuli, Valerie Dicenta, Zoi Laspa, Manuel Sigle, Tobias Harm, Tatsiana Castor, Anne-Katrin Rohlfing, Meinrad Paul Gawaz
Read the Full Article on ScienceDirect.

Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Apr 3, 2026, 17:59A Free Hemoglobin Screening Camp for Kaikadi Vasti and Eramushti Community Women – Hope Foundation Sironcha
-
Apr 3, 2026, 17:53Carlos Henrique Del Carlo: HFpEF and Iron Deficiency – Why Treating the Mitochondrial Engine Matters More Than We Thought?
-
Apr 3, 2026, 17:46Michelle Leona Cecil: A Call to Protect Patient Care and The Nation’s Blood Supply for Blood Disorders Community
-
Apr 3, 2026, 17:38Shahab Sheikhalishahi: A Rare Case of Portal Vein Thrombosis After Echis Carinatus Envenomation
-
Apr 3, 2026, 17:33Kimberly Ha: Epia Neuro Aims to Restore Movement in Stroke Survivors
-
Apr 3, 2026, 17:28Ryan Perry: Heart and Stroke Announces 2026 Grants-in-Aid Indigenous Research Stream Funding Opportunity
-
Apr 3, 2026, 17:21Maxime Dely: A Meaningful Journey of 14 years in Blood Transfusion
-
Apr 3, 2026, 17:19Arun V J: Don’t Miss TRANSCON 2026 – A Direct Pathway Into India’s Clinical and Institutional Network
-
Apr 3, 2026, 17:17Louise St. Germain Bannon: Preparating for ISTH 2026 and Highlighting Best Aspects of Congress